ArticleBMC gastroenterology2020

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.

Maximilian Sieg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.